sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction
Heart failure is the most frequent cardiac complication of chronic kidney disease (CKD). Biomarkers help identify high-risk patients. Natriuretic peptides (BNP and NT-proBNP) are largely used for monitoring patients with cardiac failure but are highly dependent on glomerular filtration rate (GFR). S...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2018/3952526 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562075700822016 |
|---|---|
| author | Maëlle Plawecki Marion Morena Nils Kuster Leila Chenine Hélène Leray-Moragues Bernard Jover Pierre Fesler Manuela Lotierzo Anne-Marie Dupuy Kada Klouche Jean-Paul Cristol |
| author_facet | Maëlle Plawecki Marion Morena Nils Kuster Leila Chenine Hélène Leray-Moragues Bernard Jover Pierre Fesler Manuela Lotierzo Anne-Marie Dupuy Kada Klouche Jean-Paul Cristol |
| author_sort | Maëlle Plawecki |
| collection | DOAJ |
| description | Heart failure is the most frequent cardiac complication of chronic kidney disease (CKD). Biomarkers help identify high-risk patients. Natriuretic peptides (BNP and NT-proBNP) are largely used for monitoring patients with cardiac failure but are highly dependent on glomerular filtration rate (GFR). Soluble suppression of tumorigenicity 2 (sST2) biomarker is well identified in risk stratification of cardiovascular (CV) events in heart failure. Furthermore, sST2 is included in a bioclinical score to stratify mortality risk. The aims of this study were to evaluate (i) the interest of circulating sST2 level in heart dysfunction and (ii) the bioclinical score (Barcelona Bio-Heart Failure risk calculator) to predict the risk of composite outcome (major adverse coronary events) and mortality in the CKD population. A retrospective study was carried out on 218 CKD patients enrolled from 2004 to 2015 at Montpellier University Hospital. sST2 was measured by ELISA (Presage ST2® kit). GFR was estimated by the CKD-EPI equation (eGFR). Indices of cardiac parameters were performed by cardiac echography. No patient had reduced ejection fraction. 112 patients had left ventricular hypertrophy, and 184 presented cardiac dysfunction, with structural, functional abnormalities or both. sST2 was independent of age and eGFR (ρ=0.05, p=0.44, and ρ=−0.07, p=0.3, respectively). Regarding echocardiogram data, sST2 was correlated with left ventricular mass index (ρ=0.16, p=0.02), left atrial diameter (ρ=0.14, p=0.04), and volume index (ρ=0.13, p=0.05). sST2 alone did not change risk prediction of death and/or CV events compared to natriuretic peptides. Included in the Barcelona Bio-Heart Failure (BCN Bio-HF) score, sST2 added value and better stratified the risk of CV events and/or death in CKD patients (p<0.0001). To conclude, sST2 was associated with cardiac remodeling independently of eGFR, unlike other cardiac biomarkers. Added to the BCN Bio-HF score, the risk stratification of death and/or CV events in nondialyzed CKD patients was highly improved. |
| format | Article |
| id | doaj-art-c074d6e1d66d4eb18c34f5be362d0ba3 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-c074d6e1d66d4eb18c34f5be362d0ba32025-02-03T01:23:31ZengWileyMediators of Inflammation0962-93511466-18612018-01-01201810.1155/2018/39525263952526sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk PredictionMaëlle Plawecki0Marion Morena1Nils Kuster2Leila Chenine3Hélène Leray-Moragues4Bernard Jover5Pierre Fesler6Manuela Lotierzo7Anne-Marie Dupuy8Kada Klouche9Jean-Paul Cristol10Département de Biochimie-Hormonologie, CHU Montpellier, Université de Montpellier, Montpellier, FranceDépartement de Biochimie-Hormonologie, CHU Montpellier, Université de Montpellier, Montpellier, FranceDépartement de Biochimie-Hormonologie, CHU Montpellier, Université de Montpellier, Montpellier, FranceDépartement de Néphrologie, CHU Montpellier, Université de Montpellier, Montpellier, FranceDépartement de Néphrologie, CHU Montpellier, Université de Montpellier, Montpellier, FrancePhyMedExp, Université de Montpellier, CNRS, INSERM, Montpellier, FrancePhyMedExp, Université de Montpellier, CNRS, INSERM, Montpellier, FranceDépartement de Biochimie-Hormonologie, CHU Montpellier, Université de Montpellier, Montpellier, FranceDépartement de Biochimie-Hormonologie, CHU Montpellier, Université de Montpellier, Montpellier, FrancePhyMedExp, Université de Montpellier, CNRS, INSERM, Montpellier, FranceDépartement de Biochimie-Hormonologie, CHU Montpellier, Université de Montpellier, Montpellier, FranceHeart failure is the most frequent cardiac complication of chronic kidney disease (CKD). Biomarkers help identify high-risk patients. Natriuretic peptides (BNP and NT-proBNP) are largely used for monitoring patients with cardiac failure but are highly dependent on glomerular filtration rate (GFR). Soluble suppression of tumorigenicity 2 (sST2) biomarker is well identified in risk stratification of cardiovascular (CV) events in heart failure. Furthermore, sST2 is included in a bioclinical score to stratify mortality risk. The aims of this study were to evaluate (i) the interest of circulating sST2 level in heart dysfunction and (ii) the bioclinical score (Barcelona Bio-Heart Failure risk calculator) to predict the risk of composite outcome (major adverse coronary events) and mortality in the CKD population. A retrospective study was carried out on 218 CKD patients enrolled from 2004 to 2015 at Montpellier University Hospital. sST2 was measured by ELISA (Presage ST2® kit). GFR was estimated by the CKD-EPI equation (eGFR). Indices of cardiac parameters were performed by cardiac echography. No patient had reduced ejection fraction. 112 patients had left ventricular hypertrophy, and 184 presented cardiac dysfunction, with structural, functional abnormalities or both. sST2 was independent of age and eGFR (ρ=0.05, p=0.44, and ρ=−0.07, p=0.3, respectively). Regarding echocardiogram data, sST2 was correlated with left ventricular mass index (ρ=0.16, p=0.02), left atrial diameter (ρ=0.14, p=0.04), and volume index (ρ=0.13, p=0.05). sST2 alone did not change risk prediction of death and/or CV events compared to natriuretic peptides. Included in the Barcelona Bio-Heart Failure (BCN Bio-HF) score, sST2 added value and better stratified the risk of CV events and/or death in CKD patients (p<0.0001). To conclude, sST2 was associated with cardiac remodeling independently of eGFR, unlike other cardiac biomarkers. Added to the BCN Bio-HF score, the risk stratification of death and/or CV events in nondialyzed CKD patients was highly improved.http://dx.doi.org/10.1155/2018/3952526 |
| spellingShingle | Maëlle Plawecki Marion Morena Nils Kuster Leila Chenine Hélène Leray-Moragues Bernard Jover Pierre Fesler Manuela Lotierzo Anne-Marie Dupuy Kada Klouche Jean-Paul Cristol sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction Mediators of Inflammation |
| title | sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction |
| title_full | sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction |
| title_fullStr | sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction |
| title_full_unstemmed | sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction |
| title_short | sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk Prediction |
| title_sort | sst2 as a new biomarker of chronic kidney disease induced cardiac remodeling impact on risk prediction |
| url | http://dx.doi.org/10.1155/2018/3952526 |
| work_keys_str_mv | AT maelleplawecki sst2asanewbiomarkerofchronickidneydiseaseinducedcardiacremodelingimpactonriskprediction AT marionmorena sst2asanewbiomarkerofchronickidneydiseaseinducedcardiacremodelingimpactonriskprediction AT nilskuster sst2asanewbiomarkerofchronickidneydiseaseinducedcardiacremodelingimpactonriskprediction AT leilachenine sst2asanewbiomarkerofchronickidneydiseaseinducedcardiacremodelingimpactonriskprediction AT heleneleraymoragues sst2asanewbiomarkerofchronickidneydiseaseinducedcardiacremodelingimpactonriskprediction AT bernardjover sst2asanewbiomarkerofchronickidneydiseaseinducedcardiacremodelingimpactonriskprediction AT pierrefesler sst2asanewbiomarkerofchronickidneydiseaseinducedcardiacremodelingimpactonriskprediction AT manuelalotierzo sst2asanewbiomarkerofchronickidneydiseaseinducedcardiacremodelingimpactonriskprediction AT annemariedupuy sst2asanewbiomarkerofchronickidneydiseaseinducedcardiacremodelingimpactonriskprediction AT kadaklouche sst2asanewbiomarkerofchronickidneydiseaseinducedcardiacremodelingimpactonriskprediction AT jeanpaulcristol sst2asanewbiomarkerofchronickidneydiseaseinducedcardiacremodelingimpactonriskprediction |